Doctors Note Logo

Published on: 9/24/2026

What medications are used to lower artery plaque?

Several medication classes are used to shrink, stabilize, or slow arterial plaque, and high-intensity statins such as atorvastatin and rosuvastatin remain the best-proven option for actual plaque regression. When statins alone are not enough, doctors often add ezetimibe, PCSK9 inhibitors like evolocumab or alirocumab, bempedoic acid, inclisiran, or icosapent ethyl to drive LDL cholesterol far lower, while aspirin and blood pressure drugs reduce clot and rupture risk without directly removing plaque. Dosing, combination choices, side effects like muscle aches, and how quickly plaque responds vary widely by person, so there are several important factors to consider before assuming one drug is right for you. See below to understand more about how each medication works, who benefits most, and what results to expect.

Because chest pressure, breathlessness, leg pain, or fatigue can signal narrowing arteries that need urgent evaluation rather than a simple prescription change, it helps to clarify your symptoms before your next appointment. Take a free, instant, online symptom check to better understand what may be driving your symptoms and to plan smart next steps with a clinician.

Last reviewed for medical accuracy: 09/24/2026

answer background

Explanation

Medications to Lower Artery Plaque: How to Reduce Plaque in Arteries

Artery plaque (atherosclerosis) develops when cholesterol, fat, and other substances build up on vessel walls. Over time, this narrows arteries, reducing blood flow and raising the risk of heart attack or stroke. Medications play a central role in slowing, stabilizing, and even reversing plaque buildup. Below is an overview of the main drug classes used to lower artery plaque and practical tips on how to reduce plaque in arteries.


1. Statins (HMG-CoA Reductase Inhibitors)

Statins are the cornerstone of plaque-lowering therapy. They block the liver enzyme HMG-CoA reductase, reducing cholesterol production and lowering LDL (“bad”) cholesterol.

  • Common options:
    • Atorvastatin (Lipitor)
    • Rosuvastatin (Crestor)
    • Simvastatin (Zocor)
  • Benefits:
    • 20–60% drop in LDL cholesterol
    • Plaque stabilization and modest regression
    • Reduced risk of heart attack, stroke, and death
  • Possible side effects:
    • Muscle aches or weakness
    • Mild liver enzyme elevations
    • Rare: severe muscle injury (rhabdomyolysis)

Statins also have anti-inflammatory effects in artery walls, helping prevent new plaque formation. Regular blood tests monitor cholesterol levels and liver function.


2. Ezetimibe

Ezetimibe (Zetia) lowers cholesterol by blocking its absorption in the small intestine. It’s often added when statins alone don’t hit LDL targets.

  • Typical use:
    • Combined with a statin for extra LDL reduction (15–20%)
  • Benefits:
    • Further plaque stabilization
    • Well tolerated, minimal side effects
  • Side effects:
    • Rare digestive upset
    • Occasional muscle aches when combined with statins

Ezetimibe is a good option for those who can’t tolerate high-dose statins.


3. PCSK9 Inhibitors

PCSK9 inhibitors are newer, powerful cholesterol-lowering injections given every 2–4 weeks.

  • Examples:
    • Evolocumab (Repatha)
    • Alirocumab (Praluent)
  • Benefits:
    • Up to 60% additional LDL reduction on top of statins
    • Demonstrated plaque regression on imaging
  • Side effects:
    • Injection-site reactions
    • Flu-like symptoms in a small number of patients
  • Considerations:
    • Higher cost—often reserved for those at very high risk or with familial hypercholesterolemia

These drugs work by preventing PCSK9 protein from degrading LDL receptors, allowing more cholesterol to be cleared from blood.


4. Bile Acid Sequestrants

Bile acid sequestrants bind bile acids in the gut, forcing the liver to use excess cholesterol to produce more bile.

  • Medications:
    • Cholestyramine (Prevalite)
    • Colesevelam (Welchol)
  • Benefits:
    • 10–20% LDL cholesterol reduction
    • Useful in combination therapy
  • Side effects:
    • Constipation, bloating, gas
    • May interfere with absorption of other drugs (take other medications 1 hour before or 4 hours after)

These are less commonly used today but remain an option for statin-intolerant patients.


5. Niacin (Vitamin B3)

Niacin can raise HDL (“good”) cholesterol and lower LDL.

  • Typical effects:
    • 15–20% drop in LDL
    • 20–30% rise in HDL
  • Side effects:
    • Flushing, itching (minimized with extended-release forms or aspirin pre-dose)
    • Elevated blood sugar or uric acid
  • Notes:
    • Used less often now due to side-effect profile and modest plaque benefits

Niacin may be considered if HDL levels remain low despite lifestyle changes.


6. Fibrates

Fibrates primarily lower triglycerides and modestly boost HDL.

  • Common agents:
    • Fenofibrate (Tricor)
    • Gemfibrozil (Lopid)
  • Effects:
    • 20–50% triglyceride reduction
    • 10–15% HDL increase
  • Side effects:
    • Digestive upset
    • Rare muscle issues when combined with statins

Fibrates are chosen when high triglycerides pose an additional risk.


7. Antiplatelet Therapy

While not directly lowering plaque, antiplatelet drugs reduce the risk of clot formation on unstable plaque.

  • Low-dose aspirin (75–100 mg daily)
  • P2Y12 inhibitors (clopidogrel, prasugrel) in select cases
  • Benefits:
    • Lower risk of heart attack or stroke due to plaque rupture
  • Caution:
    • Increased bleeding risk—discuss with your healthcare provider

Combination Therapy and Treatment Goals

To maximize how to reduce plaque in arteries and improve outcomes:

  • High-intensity statin + ezetimibe if LDL > 70 mg/dL in high-risk patients
  • Statin + PCSK9 inhibitor if familial high cholesterol or very high risk
  • Statin + bile acid sequestrant if statin-intolerant or additional LDL lowering needed

Guidelines recommend aiming for:

  • LDL cholesterol < 70 mg/dL in very high-risk individuals
  • LDL < 100 mg/dL in moderate-risk cases

Regular follow-up with lipid panels and liver tests is critical to ensure safety and efficacy.


Safety, Monitoring, and When to Seek Help

Before starting any plaque-lowering medication, your doctor will:

  • Review medical history, allergies, and current medications
  • Order baseline blood tests (lipid panel, liver function, kidney function)
  • Discuss potential side effects and how to report them

Ongoing monitoring includes:

  • Lipid levels every 6–12 weeks until targets are met
  • Liver and kidney function tests as needed
  • Checking for muscle pain, dark urine, or unexplained fatigue

If you experience any of the following, contact a healthcare professional promptly:

  • Severe muscle pain or weakness
  • Yellowing of the skin or eyes (jaundice)
  • Dark-colored urine
  • Sudden, severe shortness of breath or chest pain

For peace of mind, you might consider a free, online symptom check, using the doctor approved Ubie Symptom Checker.


Lifestyle Changes: The Foundation of Plaque Reduction

Medications work best alongside healthy habits. Here’s how to reduce plaque in arteries through lifestyle:

• Heart-healthy diet
– Emphasize fruits, vegetables, whole grains, lean proteins, and healthy fats (olive oil, nuts)
– Limit saturated fat (red meat, full-fat dairy), trans fats, and processed foods

• Regular physical activity
– Aim for at least 150 minutes of moderate exercise per week (walking, swimming, cycling)
– Include muscle-strengthening activities twice a week

• Smoking cessation
– Quitting smoking significantly slows plaque progression and improves blood vessel function

• Weight management
– Achieve and maintain a healthy weight (BMI 18.5–24.9) to lower cholesterol and blood pressure

• Stress reduction
– Techniques like meditation, yoga, or deep breathing can help control blood pressure

These habits enhance medication effects and tackle other risk factors such as high blood pressure and diabetes.


Final Thoughts

Medications are powerful tools to reduce artery plaque when paired with lifestyle changes. Statins, ezetimibe, PCSK9 inhibitors, and other agents each play a specific role in lowering LDL cholesterol, stabilizing plaque, and preventing complications. Tracking lab results and watching for side effects helps ensure safe, effective treatment.

Always talk with your doctor about the best treatment plan for you. If you’re ever unsure whether a symptom is serious, speak to a healthcare professional or try a free, online symptom check, using the doctor approved Ubie Symptom Checker.

For any sign of life-threatening or serious conditions—chest pain, sudden weakness, fainting, or severe shortness of breath—call emergency services immediately. Your health matters: speak to a doctor before making any major changes to medications or lifestyle.

(References)

  • * Nicholls SJ, Puri R, Anderson T, Ballantyne CM, Cho L, Kastelein JJ, Koenig W, Somaratne R, Kassahun H, Yang J, Wasserman SM, Scott R, Ungi I, Podolec J, Ophuis AO, Cornel JH, Borgman M, Brennan DM, Nissen SE. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. JAMA. 2016 Dec 13;316(22):2373-2384. doi: 10.1001/jama.2016.16951. PMID: 27846344.

  • * Lee SE, Chang HJ, Sung JM, Park HB, Heo R, Rizvi A, Lin FY, Kumar A, Hadamitzky M, Kim YJ, Conte E, Andreini D, Pontone G, Budoff MJ, Gottlieb I, Lee BK, Chun EJ, Cademartiri F, Maffei E, Marques H, Leipsic JA, Shin S, Choi JH, Chinnaiyan K, Raff G, Virmani R, Samady H, Stone PH, Berman DS, Narula J, Shaw LJ, Bax JJ, Min JK. Effects of Statins on Coronary Atherosclerotic Plaques: The PARADIGM Study. JACC Cardiovasc Imaging. 2018 Oct;11(10):1475-1484. doi: 10.1016/j.jcmg.2018.04.015. Epub 2018 Jun 13. PMID: 29909109.

  • * Almeida SO, Budoff M. Effect of statins on atherosclerotic plaque. Trends Cardiovasc Med. 2019 Nov;29(8):451-455. doi: 10.1016/j.tcm.2019.01.001. Epub 2019 Jan 7. PMID: 30642643.

  • * Drobni ZD, Alvi RM, Taron J, Zafar A, Murphy SP, Rambarat PK, Mosarla RC, Lee C, Zlotoff DA, Raghu VK, Hartmann SE, Gilman HK, Gong J, Zubiri L, Sullivan RJ, Reynolds KL, Mayrhofer T, Zhang L, Hoffmann U, Neilan TG. Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque. Circulation. 2020 Dec 15;142(24):2299-2311. doi: 10.1161/CIRCULATIONAHA.120.049981. Epub 2020 Oct 2. PMID: 33003973; PMCID: PMC7736526.

  • * Dawson LP, Lum M, Nerleker N, Nicholls SJ, Layland J. Coronary Atherosclerotic Plaque Regression: JACC State-of-the-Art Review. J Am Coll Cardiol. 2022 Jan 4;79(1):66-82. doi: 10.1016/j.jacc.2021.10.035. PMID: 34991791.

  • * Räber L, Ueki Y, Otsuka T, Losdat S, Häner JD, Lonborg J, Fahrni G, Iglesias JF, van Geuns RJ, Ondracek AS, Radu Juul Jensen MD, Zanchin C, Stortecky S, Spirk D, Siontis GCM, Saleh L, Matter CM, Daemen J, Mach F, Heg D, Windecker S, Engstrøm T, Lang IM, Koskinas KC, PACMAN-AMI collaborators. Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical Trial. JAMA. 2022 May 10;327(18):1771-1781. doi: 10.1001/jama.2022.5218. PMID: 35368058; PMCID: PMC8978048.

  • * Nicholls SJ, Kataoka Y, Nissen SE, Prati F, Windecker S, Puri R, Hucko T, Aradi D, Herrman JR, Hermanides RS, Wang B, Wang H, Butters J, Di Giovanni G, Jones S, Pompili G, Psaltis PJ. Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction. JACC Cardiovasc Imaging. 2022 Jul;15(7):1308-1321. doi: 10.1016/j.jcmg.2022.03.002. Epub 2022 Mar 16. PMID: 35431172.

  • * Sarraju A, Nissen SE. Atherosclerotic plaque stabilization and regression: a review of clinical evidence. Nat Rev Cardiol. 2024 Jul;21(7):487-497. doi: 10.1038/s41569-023-00979-8. Epub 2024 Jan 4. PMID: 38177454.

  • * Ueki Y, Itagaki T, Kuwahara K. Lipid-lowering Therapy and Coronary Plaque Regression. J Atheroscler Thromb. 2024 Nov 1;31(11):1479-1495. doi: 10.5551/jat.RV22024. Epub 2024 Aug 8. PMID: 39111840; PMCID: PMC11537793.

  • * Koskinas KC, Häner J, Ueki Y, Otsuka T, Lonborg J, Shibutani H, Kakizaki R, Kaiser C, van Geuns RJ, Ondracek AS, Praz F, Ambühl M, Spirk D, Lanz J, Daemen J, Heg D, Mayr M, Mach F, Windecker S, Engstrøm T, Lang IM, von Eckardstein A, Losdat S, Räber L. Association of Lipoprotein(a) With Changes in Coronary Atherosclerosis in Patients Treated With Alirocumab. Circ Cardiovasc Imaging. 2024 Nov;17(11):e016683. doi: 10.1161/CIRCIMAGING.124.016683. Epub 2024 Nov 19. PMID: 39561225.

Thinking about asking ChatGPT?Ask me instead

Tell your friends about us.

We would love to help them too.

smily Shiba-inu looking

For First Time Users

What is Ubie’s Doctor’s Note?

We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.

Was this page helpful?

Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.